Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo | Citedby Results | Clinical Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo

Clin Cancer Res (2018) 24 (12): 2901–2912.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Hannah L. Smith
Elaine Willmore
Lisa Prendergast
Nicola J. Curtin

British Journal of Cancer (2024) 131 (5): 905.

Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment

Luisa Maresca
Barbara Stecca
Laura Carrassa

Cells (2022) 11 (9): 1466.

Mechanisms used by cancer cells to tolerate drug-induced replication stress

Hendrika A. Segeren
Bart Westendorp

Cancer Letters (2022) 544: 215804.

Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53

Hendrika A. Segeren
Elsbeth A. van Liere
Frank M. Riemers
Alain de Bruin
Bart Westendorp

Oncogene (2022) 41 (19): 2719.

PTEN: A novel target for vitamin D in melanoma

Artur Shariev
Nicole Painter
Vivienne E. Reeve
Nikolas K. Haass
Mark S. Rybchyn
Furkan A. Ince
Rebecca S. Mason
Katie M. Dixon

The Journal of Steroid Biochemistry and Molecular Biology (2022) 218: 106059.

BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors

Sean A. Misek
Bardees M. Foda
Thomas S. Dexheimer
Maisah Akram
Susan E. Conrad
Jens C. Schmidt
Richard R. Neubig
Kathleen A. Gallo

Frontiers in Oncology (2022) 12

Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors

You Pan
Yuchao Yang
Rong Huang
Huawei Yang
Qinghua Huang
Yinan Ji
Jingxing Dai
Kun Qiao
Wei Tang
Longgui Xie
Ming Yin
Jun Ouyang
Shipeng Ning
Danke Su

Breast Cancer Research (2022) 24 (1)

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

Martina Proctor
Jazmina L. Gonzalez Cruz
Sheena M. Daignault-Mill
Margaret Veitch
Bijun Zeng
Anna Ehmann
Muhammed Sabdia
Cameron Snell
Colm Keane
Riccardo Dolcetti
Nikolas K. Haass
James W. Wells
Brian Gabrielli

Cancers (2021) 13 (15): 3733.

Identification of key candidate genes and pathways in anaplastic thyroid cancer by bioinformatics analysis

Yong-Gang Ding
Yu-Lin Ren
Yang-Shan Xu
Chang-Sheng Wei
Yong-Bin Zhang
Shou-Kai Zhang
Chang-An Guo

American Journal of Otolaryngology (2020) 41 (3): 102434.

Identification of the molecular mechanisms associated with acute type A aortic dissection through bioinformatics methods

Tao Jiang
Liangyi Si

Brazilian Journal of Medical and Biological Research (2019) 52 (11)

Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer

Deborah Nazareth
Mathew J. K. Jones
Brian Gabrielli

Cancers (2019) 11 (9): 1320.

Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine

Zay Yar Oo
Martina Proctor
Alexander J. Stevenson
Deborah Nazareth
Madushan Fernando
Sheena M. Daignault
Catherine Lanagan
Sebastian Walpole
Vanessa Bonazzi
Dubravka Škalamera
Cameron Snell
Nikolas K. Haass
Jill E. Larsen
Brian Gabrielli

Molecular Oncology (2019) 13 (7): 1503.

Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells

Kiyohiro Ando
Yohko Nakamura
Hiroki Nagase
Akira Nakagawara
Tsugumichi Koshinaga
Satoshi Wada
Makoto Makishima

International Journal of Molecular Sciences (2019) 20 (15): 3700.